Locations:
Search IconSearch
August 20, 2014/Cancer/News & Insight

Guidelines for Peripheral Blood Progenitor Cell Mobilization

Address optimal progenitor cell mobilization strategies for hematopoietic cell transplant

DrDoung_690x380

There are many ways to mobilize peripheral blood progenitor cells, including growth factor or chemotherapy in combination with growth factor, both of which can be enhanced with plerixafor, a fairly new option. Historically, hospitals have applied different protocols and algorithms depending on what resources they had available specifically because mobilization requires coordination between different departments (apheresis, transfusion medicine, flow cytometry) and not every hospital has similar access/availability to these departments.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Because of the imperative need to collect progenitor cells safely, adequately, and cost-effectively and for transplant and to attempt to standardize practices, The American Society of Blood and Marrow Transplantation (ASBMT) set a task force, led by Hien K. Duong, MD, Hematology and Oncology, Cleveland Clinic, to publish evidence-based guidelines for peripheral blood progenitor cell mobilization.

Impact of Plerixafor

With the FDA approval of plerixafor as a mobilizing agent in 2008, a large body of papers and abstracts detailed mobilization and improved efficiency in collection under varied circumstances. Dr. Duong and the ASBMT Practice Guidelines Committee began the process with a thorough literature review of these publications. Dr. Duong and the ASBMT Committee defined evidence-based recommendations to hopefully improve practices throughout the country, whether for small or large hospitals with varying resources.

They address clinical questions such as which growth factor is optimal, what chemotherapy and dose is most effective and when to initiate leukapheresis. The detailed guidelines were peer reviewed by a national expert base representing small and large hospitals and approved by the American Society of Blood and Marrow Transplantation before published in Biology of Blood and Marrow Transplantation.

“We lay out the known risks and benefits, advantages and disadvantages, of each mobilization strategy. We also recommend target cell doses for collection and infusion for transplant. We present data on how cell collection can most safely and effectively be done,” says Dr. Duong. The standardized algorithms address the optimal resource accessibility, and may help smaller transplant programs justify investment in necessary service enhancements. The guidelines even include a list of frequently asked questions, as part of the goal to provide comprehensive guidance.

Advertisement

Photo by Russell Lee.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad